Onkologie. 2025:19(5):263-267 | DOI: 10.36290/xon.2025.048

Treatment of SCLC (Small Cell Lung Cancer)

Marie Drösslerová
Pneumologická klinika 1. LF UK a Fakultní Thomayerova nemocnice v Praze

Small cell lung cancer (SCLC) is a type of bronchogenic carcinoma characterized by rapid growth. Initially, it shows marked chemosensitivity and radiosensitivity. Current standard treatment approaches also include immunotherapy. Despite significant advances in SCLC treatment in recent years, the overall prognosis remains poor for most patients. This is due to the tumor's highly aggressive biological behavior, with a typically high relapse rate and subsequent resistance to further therapy. As a result, intensive research is underway into new therapeutic strategies, including targeted therapy and combination regimens.

Keywords: small cell lung cancer (SCLC), treatment, immunotherapy, bispecific T-cell engagers (BiTEs).

Accepted: November 25, 2025; Published: December 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drösslerová M. Treatment of SCLC (Small Cell Lung Cancer). Onkologie. 2025;19(5):263-267. doi: 10.36290/xon.2025.048.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 15.12.2026

    References

    1. Senan S, Okamoto I, Lee GW, et al. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. Clin Lung Cancer. 2020;21(2):e84-e88. Go to original source... Go to PubMed...
    2. Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N Engl J Med. 2024;391(14):1313-1327. Go to original source... Go to PubMed...
    3. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220-2229. Go to original source... Go to PubMed...
    4. Reck M, Dziadziuszko R, Sugawara S, et al. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study. Lung Cancer. 2024 Oct;196:107924. Go to original source... Go to PubMed...
    5. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-1939. Go to original source... Go to PubMed...
    6. Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51-65. Go to original source... Go to PubMed...
    7. Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment. Clin Pharmacol Ther. 2017;101(5): 634-645. Go to original source... Go to PubMed...
    8. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317(9):1255-1260. Go to original source... Go to PubMed...
    9. Amgen Inc. IMDELLTRA™ (tarlatamab-dlle): US prescribing information. 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761344s000lbl.pdf.Accessed 10 August 2025.
    10. Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023;389(22):2063-2075. Go to original source... Go to PubMed...
    11. Mountzios G, Sun L, Cho BC, et al. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. N Engl J Med. 2025;393(4):349-361. Go to original source... Go to PubMed...
    12. Wermke M, Gambardella V, Kuboki Y, et al. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. J Clin Oncol. 2025 Jul 24: JCO2500363. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.